Nature

HIV-1 Reverse Transcriptase Inhibitors and Drug Resistance

HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...
Medscape

Etravirine: A Novel Nonnucleoside Reverse Transcriptase Inhibitor for Managing Human Immunodeficiency Virus Infection

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.
Medscape

Resistance Associated With Reverse Transcriptase Inhibitors

At the 12th International HIV Drug Resistance Workshop, held June 10-14, 2003, in Los Cabos, Mexico, investigators from around the world provided the latest results from studies of resistance topics ...
The American Journal of Managed Care

Controlling Spread of Drug-Resistant HIV May Necessitate Interventions

Pretreatment drug resistance (PDR) in patients with HIV varies by subtype, affecting antiretroviral therapy implementation and first-line treatment efficacy. In Hangzhou, 8.4% of newly diagnosed HIV ...
ascopubs.org

Reverse transcriptase inhibitors reduce tumor growth in vivo and induce cell differentiation

Potentiation of apoptosis inducing activity of BL-193, an inhibitor of Bcl-XL protein, by genistein in pancreatic cancer cells No significant financial relationships to disclose. This is an ASCO ...
Monthly Prescribing Reference

Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia. HealthDay News — Exposure to nucleoside reverse transcriptase inhibitors ...
BioWorld

Rome Therapeutics divulges new L1RE1 and HERV-K reverse transcriptase inhibitors

Rome Therapeutics Inc. has synthesized 4’-halomethyl-cytidine phosphoramidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors ...
Business Insider

ROME Therapeutics Debuts First Preclinical Data of its LINE-1 Reverse Transcriptase (RT) Inhibitors in Neurodegenerative Diseases at 3rd Annual Dark Genome Symposium

BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- ROME Therapeutics, a biotechnology company illuminating the intersection of the dark genome and innate immunity to develop breakthrough medicines for ...
Nature

HIV-1 Reverse Transcriptase Inhibitors

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...
BioWorld

Rome Therapeutics presents new inhibitors of LINE1 or HERV-K reverse transcriptase

Rome Therapeutics Inc. has divulged didehydro-3’-deoxy-4’-ethynylthymidines acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors reported to ...